Int J Oncol 50: 893-902, 2017; DOI: 10.3892/ijo.2017.3871
Subsequently to the publication of the above article, an interested reader drew to the authors' attention that Fig. 4B on p. 899, showing the results of Transwell invasion assay experiments, contained a pair of apparently overlapping panels, such that they may have been derived from the same original source, even though they were intended to show the results from differently performed experiments. After having re-examined their original data, the authors were able to identify that Fig. 4B had been inadvertently assembled incorrectly.
The revised version of Fig. 4, featuring the correct data for the SB-T-121205, 10 nM data panel (the lower-left panel in Fig. 4B), is shown on the next page. The authors confirm that these data continue to support the main conclusions presented in their paper, and are grateful to the Editor of International Journal of Oncology for allowing them this opportunity to publish a Corrigendum. They also apologize to the readership for any inconvenience caused.
SB-T-121205 inhibits the migration and invasion abilities of MCF-7/PTX cells. (A) Migration of MCF-7/PTX cells treated with paclitaxel or SB-T-121205 was determined by wound healing assay (original magnification, ×100). (B) Invasiveness of MCF-7/PTX cells treated with paclitaxel or SB-T-121205 was detected by Transwell invasion assay (original magnification, ×100). Data are shown as mean ± SD from three experiments, **P<0.01 vs. control group.